Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases, thereby extending its spectrum of activity against beta-lactamase-producing bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (in combination with an aminoglycoside for certain patients) * Bacterial meningitis (in select cases) ## Adult Dosing Standard adult dosing is typically 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) or 4.5 grams (piperacillin 4 g / tazobactam 0.5 g) intravenously every 6 hours. The choice of dose and frequency depends on the severity and type of infection. Higher doses may be used for severe infections or in patients with renal impairment who are receiving continuous renal replacement therapy. Specific dosing regimens for febrile neutropenia often involve higher doses and shorter intervals (e.g., 4.5 g every 4 hours). Dosing for specific indications may vary based on local antibiograms and institutional protocols. ## Pediatric Dosing Dosing is typically based on the piperacillin component. * **2 months to 12 years:** 100 mg piperacillin component/kg/day intravenously divided into 4 doses. The maximum dose should not exceed the adult maximum. * **Neonates and infants < 2 months:** Dosing is less established and should be guided by clinical judgment and institutional protocols, considering gestational and postnatal age. A common regimen is 75 mg piperacillin component/kg/day intravenously divided every 12 hours for premature infants (<30 weeks gestation) and every 8 hours for term infants (≥30 weeks gestation). ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: 2.25 g (piperacillin 2 g / tazobactam 0.25 g) or 3.375 g (piperacillin 3 g / tazobactam 0.375 g) IV every 8 hours. * CrCl < 20 mL/min: 2.25 g IV every 12 hours. * Hemodialysis: 2.25 g IV every 8 hours, plus an additional 0.75 g dose after each dialysis session. * Dosing adjustments for pediatric patients with renal impairment are also necessary and are often based on a fraction of the standard pediatric dose. ## Contraindications * History of hypersensitivity to piperacillin, tazobactam, other beta-lactam antibiotics (including penicillins and cephalosporins), or any component of the formulation. * Previous immediate and/or severe allergic reaction to amoxicillin/clavulanate. ## Adverse Effects Common: Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, injection site reactions. Serious: Clostridioides difficile-associated diarrhea, anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, seizures (especially with high doses or renal impairment), eosinophilia, leukopenia, neutropenia, thrombocytopenia, prolonged bleeding times. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the effect of vecuronium. * **Oral anticoagulants (e.g., warfarin):** Potential for increased INR. * **Methotrexate:** Piperacillin may decrease methotrexate serum levels. * **Live bacterial vaccines:** May reduce the efficacy of the vaccine. ## Monitoring * Renal function (baseline and periodically, especially in patients with renal impairment). * Liver function tests (periodically). * Complete blood count (may show transient eosinophilia, leukopenia, neutropenia, thrombocytopenia). * Signs and symptoms of hypersensitivity reactions. * Signs and symptoms of C. difficile infection. * Culture and sensitivity testing to guide therapy. ## Clinical Pearls * Piperacillin-tazobactam is a potent broad-spectrum agent effective against many gram-positive, gram-negative, and anaerobic bacteria, including many beta-lactamase producers. * It is often used empirically for serious infections, particularly those acquired in healthcare settings. * Dosing adjustments for renal impairment are crucial. * Monitor for hypersensitivity reactions, as cross-reactivity with other beta-lactams can occur. * Discontinue if diarrhea develops and consider testing for C. difficile. * The 4.5 g formulation contains more piperacillin per vial than the 3.375 g formulation. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for complete and up-to-date details on drug use, dosing, and safety.